“This study suggests that the treatment of a patient's underlying hypogonadism or sexual dysfunction may be protective in the use of finasteride for alopecia or BPH,” says Kevin J. Campbell, MD, MS.
In this video, Kevin J. Campbell, MD, MS, discusses the takeaways of the study, “Finasteride-Associated Suicide and Depression in Men Treated for Hypogonadism and Impotence,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Campbell is an assistant professor in the department of urology at the University of Florida, Gainesville.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.